Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
2001 1
2004 1
2005 2
2007 5
2008 2
2009 3
2010 2
2011 1
2013 3
2014 4
2015 7
2016 5
2017 6
2018 3
2019 3
2020 4
2021 5
2022 4
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Immune-related adverse events of checkpoint inhibitors.
Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Suárez-Almazor ME. Ramos-Casals M, et al. Among authors: mariette x. Nat Rev Dis Primers. 2020 May 7;6(1):38. doi: 10.1038/s41572-020-0160-6. Nat Rev Dis Primers. 2020. PMID: 32382051 Free PMC article. Review.
Management is primarily based on corticosteroids and other immunomodulatory agents, which should be prescribed carefully to reduce the potential of short-term and long-term complications. Thoughtful management of irAEs is important in optimizing quality of life and …
Management is primarily based on corticosteroids and other immunomodulatory agents, which should be prescribed carefully to reduce the poten …
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D. Smolen JS, et al. Among authors: mariette x. Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Ann Rheum Dis. 2017. PMID: 28264816 Free article. Review.
As first strategy, the Task Force recommends MTX (rapid escalation to 25 mg/week) plus short-term GC, aiming at >50% improvement within 3 and target attainment within 6 months. ...Without unfavourable prognostic markers, switching to-or adding-another csDMARDs (plus sho …
As first strategy, the Task Force recommends MTX (rapid escalation to 25 mg/week) plus short-term GC, aiming at >50% improvement w …
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme.
Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. Cohen SB, et al. Among authors: mariette x. RMD Open. 2020 Oct;6(3):e001395. doi: 10.1136/rmdopen-2020-001395. RMD Open. 2020. PMID: 33127856 Free PMC article. Clinical Trial.
We report the largest integrated safety analysis of tofacitinib, as of March 2017, using data from phase I, II, III, IIIb/IV and long-term extension studies in adult patients with RA. METHODS: Data were pooled for patients with RA who received 1 tofacitinib dose. ...
We report the largest integrated safety analysis of tofacitinib, as of March 2017, using data from phase I, II, III, IIIb/IV and long-ter …
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort.
Comarmond C, Pagnoux C, Khellaf M, Cordier JF, Hamidou M, Viallard JF, Maurier F, Jouneau S, Bienvenu B, Puéchal X, Aumaître O, Le Guenno G, Le Quellec A, Cevallos R, Fain O, Godeau B, Seror R, Dunogué B, Mahr A, Guilpain P, Cohen P, Aouba A, Mouthon L, Guillevin L; French Vasculitis Study Group. Comarmond C, et al. Arthritis Rheum. 2013 Jan;65(1):270-81. doi: 10.1002/art.37721. Arthritis Rheum. 2013. PMID: 23044708 Free article.
This study was undertaken to describe the main characteristics of a larger patient cohort and their long-term outcomes. METHODS: A retrospective study of EGPA patients in the French Vasculitis Study Group cohort who satisfied the American College of Rheumatology criteria a …
This study was undertaken to describe the main characteristics of a larger patient cohort and their long-term outcomes. METHODS: A re …
Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force.
Strehl C, Bijlsma JW, de Wit M, Boers M, Caeyers N, Cutolo M, Dasgupta B, Dixon WG, Geenen R, Huizinga TW, Kent A, de Thurah AL, Listing J, Mariette X, Ray DW, Scherer HU, Seror R, Spies CM, Tarp S, Wiek D, Winthrop KL, Buttgereit F. Strehl C, et al. Among authors: mariette x. Ann Rheum Dis. 2016 Jun;75(6):952-7. doi: 10.1136/annrheumdis-2015-208916. Epub 2016 Mar 1. Ann Rheum Dis. 2016. PMID: 26933146 Review.
As a first step to improve implementation, we aimed at defining conditions under which long-term glucocorticoid therapy may have an acceptably low level of harm. ...The group agreed that the risk of harm is low for the majority of patients at long-term dosages of 5 …
As a first step to improve implementation, we aimed at defining conditions under which long-term glucocorticoid therapy may have an a …
Long COVID: a new word for naming fibromyalgia?
Mariette X. Mariette X. Ann Rheum Dis. 2024 Jan 2;83(1):12-14. doi: 10.1136/ard-2023-224848. Ann Rheum Dis. 2024. PMID: 37923365
However, "Naming things wrongly adds to the world's unhappiness" was saying Albert Camus. Thus, the term of long COVID, which suggests viral persistence of impaired immune response to the virus, is unappropriated and should be replaced by fibromyalgia-like post-COVID syndr …
However, "Naming things wrongly adds to the world's unhappiness" was saying Albert Camus. Thus, the term of long COVID, which suggest …
French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides).
Terrier B, Darbon R, Durel CA, Hachulla E, Karras A, Maillard H, Papo T, Puechal X, Pugnet G, Quemeneur T, Samson M, Taille C, Guillevin L; Collaborators. Terrier B, et al. Orphanet J Rare Dis. 2020 Dec 29;15(Suppl 2):351. doi: 10.1186/s13023-020-01621-3. Orphanet J Rare Dis. 2020. PMID: 33372616 Free PMC article. Review.
The management goals are: to obtain remission and, in the long term, healing; to reduce the risk of relapses; to limit and reduce the sequelae linked to the disease; to limit the side effects and the sequelae linked to the treatments; to improve or at least maintain the be …
The management goals are: to obtain remission and, in the long term, healing; to reduce the risk of relapses; to limit and reduce the …
Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome.
Noel N, Dutasta F, Costedoat-Chalumeau N, Bienvenu B, Mariette X, Geffray L, Sene D, Chaidi RB, Michot JM, Fain O, Darnige L, Ankri A, Cacoub P, Piette JC, Saadoun D. Noel N, et al. Among authors: mariette x. Autoimmun Rev. 2015 Aug;14(8):680-5. doi: 10.1016/j.autrev.2015.03.007. Epub 2015 Apr 9. Autoimmun Rev. 2015. PMID: 25864630 Review.
BACKGROUND: Long-term anticoagulation is recommended in antiphospholipid syndrome with thrombosis in order to prevent recurrences. While the current mainstay relies on vitamin K antagonists, their long-term maintenance may remain challenging. OBJECTIVES: To report o …
BACKGROUND: Long-term anticoagulation is recommended in antiphospholipid syndrome with thrombosis in order to prevent recurrences. Wh …
Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.
Bykerk VP, Cush J, Winthrop K, Calabrese L, Lortholary O, de Longueville M, van Vollenhoven R, Mariette X. Bykerk VP, et al. Among authors: mariette x. Ann Rheum Dis. 2015 Jan;74(1):96-103. doi: 10.1136/annrheumdis-2013-203660. Epub 2013 Oct 3. Ann Rheum Dis. 2015. PMID: 24092417 Free PMC article. Review.
OBJECTIVE: To report the long-term safety data of certolizumab pegol (CZP) in rheumatoid arthritis (RA) accumulated as of 30 November 2011. ...CONCLUSIONS: No new or unexpected safety signals associated with CZP emerged in this updated long-term safety analysis. Whi …
OBJECTIVE: To report the long-term safety data of certolizumab pegol (CZP) in rheumatoid arthritis (RA) accumulated as of 30 November …
Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance.
Winthrop KL, Novosad SA, Baddley JW, Calabrese L, Chiller T, Polgreen P, Bartalesi F, Lipman M, Mariette X, Lortholary O, Weinblatt ME, Saag M, Smolen J. Winthrop KL, et al. Among authors: mariette x. Ann Rheum Dis. 2015 Dec;74(12):2107-16. doi: 10.1136/annrheumdis-2015-207841. Epub 2015 Sep 22. Ann Rheum Dis. 2015. PMID: 26395500 Review.
These findings informed a consensus committee (infectious diseases and rheumatology specialists) in deliberations regarding the development of a candidate list of infections that should be considered as OIs in the setting of biologic therapy. We reviewed 368 clinical trials (rand …
These findings informed a consensus committee (infectious diseases and rheumatology specialists) in deliberations regarding the development …
55 results